Skip to content

Attention-deficit/hyperactivity disorder — overview

TL;DR — ADHD is a lifespan neurodevelopmental disorder defined clinically by persistent, impairing inattention and/or hyperactivity-impulsivity across settings; no laboratory test establishes the diagnosis (Wolraich 2019, PMID 31570648; Peterson 2024, PMID 38523599). Prevalence depends strongly on ascertainment: a 2024 synthesis estimated 1.6% in registers, 5.0% in surveys, 4.2% in one-stage clinical studies and 4.8% in two-stage studies (Popit 2024, PMID 39381949). Common-variant risk is highly polygenic, and group-level brain, EEG and peripheral signals are not individual diagnostic tests (Demontis 2019, PMID 30478444; Kim 2020, PMID 33069318). Stimulants have the largest short-term average symptom effects, whereas long-term functional causality and individual treatment matching remain less certain (Cortese 2018, PMID 30097390; Swanson 2008, PMID 18573923).

Definition, boundary and terminology

“ADD” is historical terminology; current nosology uses ADHD with predominantly inattentive, predominantly hyperactive-impulsive, or combined presentation. Presentation is a current symptom configuration rather than a fixed lifelong subtype (Leffa 2022, PMID 35397064).

Diagnosis requires developmental history, impairment, cross-setting evidence and exclusion of better explanations. Rating scales structure evidence but do not replace clinician judgment; a 231-study review found generally low-strength and heterogeneous diagnostic-performance evidence across ratings, tests, biospecimens, EEG and imaging (Peterson 2024, PMID 38523599).

Quantitative orientation

Domain Best anchor What it means
Population prevalence Register 1.6%; survey 5.0%; one-stage clinical 4.2%; two-stage clinical 4.8% Method is part of the estimate (Popit 2024, PMID 39381949)
Adult prevalence Persistent adult ADHD 2.58%; symptomatic adult ADHD 6.76% Childhood-onset requirements materially change the denominator (Song 2021, PMID 33692893)
Persistence About 15% full-syndrome and 65% symptomatic persistence near age 25 in older follow-up synthesis “Remission” depends on threshold and outcome (Faraone 2006, PMID 16420712)
Heritability Review estimate 74%; common variants explain only part High heritability does not make a single-gene disorder or diagnostic test (Faraone 2019, PMID 29892054)
Acute medication Network of 133 double-blind RCTs Average short-term efficacy is clearer than long-term function (Cortese 2018, PMID 30097390)

Clinical and research map

Assessment, development, comorbidity and setting determine what the same symptom count means. The dedicated pages therefore separate diagnosis, lifespan epidemiology, pediatric and adult evidence, and differential diagnosis.

Treatment evidence is split between pharmacologic treatment and psychosocial and digital treatment. The MTA randomized 579 children aged 7–9.9 years; carefully managed medication and combined treatment improved core symptoms more than intensive behavioral treatment or community care at 14 months, while combined care had advantages in some non-core domains (MTA Cooperative Group 1999, PMID 10591283). Later follow-up could not preserve the original randomized contrast because treatment patterns converged (Swanson 2008, PMID 18573923).

The field’s translational bottleneck is specificity. GWAS established reproducible population-level loci, but polygenic scores, imaging classifiers, EEG and peripheral markers have not displaced clinical assessment (Demontis 2019, PMID 30478444; Kim 2020, PMID 33069318).

How to read the evidence

  • Diagnostic case–control separation is not the same as accuracy among referred patients.
  • Symptom change is not interchangeable with functional improvement.
  • Short randomized trials estimate acute efficacy, not decades-long benefit or harm.
  • Observational within-person and target-trial designs reduce some confounding but remain nonrandomized.
  • Parent, teacher, clinician, self-report and objective tasks measure different vantage points.
  • Statistical significance does not establish a patient-important effect.
  • Population averages should not be converted into deterministic individual predictions.
  • Absence of evidence in a subgroup is not evidence of identical effects.

Minimum standards for the next evidence generation

  1. Prespecify one primary outcome and its clinically important threshold.
  2. Report symptoms, function, quality of life and harms separately.
  3. Use clinically relevant comparators rather than only healthy controls.
  4. Retain and report participants who discontinue treatment.
  5. Test generalization across sex, age, ancestry, comorbidity and setting.
  6. Separate model development, internal validation and external validation.
  7. Declare medication exposure, concomitant care and rater blinding.
  8. Make null and contradictory results visible rather than averaging away design differences.

Recurring evidence gaps

  • Females, older adults and people with complex comorbidity remain underrepresented.
  • Functional outcomes are measured less consistently than core symptoms.
  • Follow-up usually ends before major educational or occupational transitions.
  • Comparator choice often makes effects look more or less specific than they are.
  • Treatment discontinuation and switching weaken long-term causal contrasts.
  • Independent replication is uncommon for biomarkers and digital interventions.

Retrieved evidence map

The following records were retrieved through this page’s six live PubMed searches. Inclusion here means the record is directly relevant to the page’s scope; it does not imply equal quality or endorsement of its conclusions.

Citation Indexed study lens Directly studied question/title Interpretation boundary
Wolraich 2019, PMID 31570648 Journal Article, Practice Guideline Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Interpret within its sampled population and comparator
Peterson 2024, PMID 38523599 Systematic Review, Journal Article Tools for the Diagnosis of ADHD in Children and Adolescents: A Systematic Review. Interpret within its sampled population and comparator
Popit 2024, PMID 39381949 Journal Article, Systematic Review Prevalence of attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis. Interpret within its sampled population and comparator
Demontis 2019, PMID 30478444 Journal Article, Meta-Analysis Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Interpret within its sampled population and comparator
Kim 2020, PMID 33069318 Journal Article, Meta-Analysis Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. Interpret within its sampled population and comparator
Cortese 2018, PMID 30097390 Comparative Study, Journal Article Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Interpret within its sampled population and comparator
Swanson 2008, PMID 18573923 Consensus Statement, Journal Article Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Interpret within its sampled population and comparator
Leffa 2022, PMID 35397064 Journal Article, Review ADHD in Children and Adults: Diagnosis and Prognosis. Interpret within its sampled population and comparator
Song 2021, PMID 33692893 Journal Article, Meta-Analysis The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. Interpret within its sampled population and comparator
Faraone 2006, PMID 16420712 Journal Article, Research Support, N.I.H., Extramural The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Interpret within its sampled population and comparator
Faraone 2019, PMID 29892054 Journal Article, Research Support, Non-U.S. Gov't Genetics of attention deficit hyperactivity disorder. Interpret within its sampled population and comparator
MTA Cooperative Group 1999, PMID 10591283 Clinical Trial, Comparative Study A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Interpret within its sampled population and comparator
Li 2024, PMID 38470385 Journal Article, Observational Study ADHD Pharmacotherapy and Mortality in Individuals With ADHD. Interpret within its sampled population and comparator
Ostinelli 2025, PMID 39701638 Comparative Study, Journal Article Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Interpret within its sampled population and comparator
Crunelle 2018, PMID 29510390 Journal Article, Consensus Statement International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. Interpret within its sampled population and comparator
Faraone 2021, PMID 33549739 Journal Article, Network Meta-Analysis The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Interpret within its sampled population and comparator
Barkley 2002, PMID 12093014 Consensus Statement, Journal Article International consensus statement on ADHD. January 2002. Interpret within its sampled population and comparator
Kutcher 2004, PMID 14659983 Consensus Statement, Guideline International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Interpret within its sampled population and comparator
Auvin 2018, PMID 30178479 Journal Article, Systematic Review Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission. Interpret within its sampled population and comparator
Barkley 2002, PMID 12447019 Letter International Consensus Statement on ADHD. Interpret within its sampled population and comparator
Spijkerman 2021, PMID 34978058 Journal Article, Consensus Statement [Adolescents with concurrent ADHD and substance use disorder; international consensus]. Interpret within its sampled population and comparator
Özgen 2020, PMID 32634814 Journal Article, Consensus Statement International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. Interpret within its sampled population and comparator
Özgen 2021, PMID 34397296 Journal Article, Consensus Statement [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder]. Interpret within its sampled population and comparator
Price 2026, PMID 42462051 Journal Article, Consensus Statement Consensus Statement on Digital Health and Attention-Deficit/Hyperactivity Disorder by the European Network for ADHD (EUNETHYDIS): Modified Delphi Study. Interpret within its sampled population and comparator
Kieling 2012, PMID 21499858 Journal Article, Review ADHD in children and adults: diagnosis and prognosis. Interpret within its sampled population and comparator
Spencer 2007, PMID 17556405 Journal Article, Review Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. Interpret within its sampled population and comparator
Schmidt 2009, PMID 19761584 Journal Article Developmental psychopathology: Attention Deficit Hyperactivity Disorder (ADHD). Interpret within its sampled population and comparator
Salari 2023, PMID 37081447 Meta-Analysis, Systematic Review The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis. Interpret within its sampled population and comparator
Polanczyk 2014, PMID 24464188 Journal Article, Meta-Analysis ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Interpret within its sampled population and comparator
Polanczyk 2007, PMID 17541055 Journal Article, Meta-Analysis The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Interpret within its sampled population and comparator
Njardvik 2025, PMID 40245462 Journal Article, Systematic Review Psychiatric comorbidity in children and adolescents with ADHD: A systematic review and meta-analysis. Interpret within its sampled population and comparator
Ayano 2023, PMID 37495084 Journal Article, Systematic Review The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. Interpret within its sampled population and comparator

Open questions

  • Which measures best distinguish symptomatic remission from durable functional recovery? (Faraone 2006, PMID 16420712)
  • Which treatment sequences improve education, work, relationships and mortality rather than ratings alone? (Cortese 2018, PMID 30097390; Li 2024, PMID 38470385)
  • Can any multimodal marker add reproducible value beyond careful clinical assessment? (Peterson 2024, PMID 38523599; Kim 2020, PMID 33069318)

References

  1. Wolraich et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144. PMID 31570648
  2. Peterson et al. Tools for the Diagnosis of ADHD in Children and Adolescents: A Systematic Review. Pediatrics. 2024;153. PMID 38523599
  3. Popit et al. Prevalence of attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis. European psychiatry : the journal of the Association of European Psychiatrists. 2024;67:e68. PMID 39381949
  4. Demontis et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature genetics. 2019;51:63-75. PMID 30478444
  5. Kim et al. Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. The lancet. Psychiatry. 2020;7:955-970. PMID 33069318
  6. Cortese et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The lancet. Psychiatry. 2018;5:727-738. PMID 30097390
  7. Swanson et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of attention disorders. 2008;12:4-14. PMID 18573923
  8. Leffa et al. ADHD in Children and Adults: Diagnosis and Prognosis. Current topics in behavioral neurosciences. 2022;57:1-18. PMID 35397064
  9. Song et al. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. Journal of global health. 2021;11:04009. PMID 33692893
  10. Faraone et al. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychological medicine. 2006;36:159-65. PMID 16420712
  11. Faraone et al. Genetics of attention deficit hyperactivity disorder. Molecular psychiatry. 2019;24:562-575. PMID 29892054
  12. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Archives of general psychiatry. 1999;56:1073-86. PMID 10591283
  13. Li et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA. 2024;331:850-860. PMID 38470385
  14. Ostinelli et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The lancet. Psychiatry. 2025;12:32-43. PMID 39701638
  15. Crunelle et al. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. European addiction research. 2018;24:43-51. PMID 29510390
  16. Faraone et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and biobehavioral reviews. 2021;128:789-818. PMID 33549739
  17. Barkley. International consensus statement on ADHD. January 2002. Clinical child and family psychology review. 2002;5:89-111. PMID 12093014
  18. Kutcher et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2004;14:11-28. PMID 14659983
  19. Auvin et al. Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission. Epilepsia. 2018;59:1867-1880. PMID 30178479
  20. Barkley. International Consensus Statement on ADHD. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1389. PMID 12447019
  21. Spijkerman et al. [Adolescents with concurrent ADHD and substance use disorder; international consensus]. Tijdschrift voor psychiatrie. 2021;63:868-874. PMID 34978058
  22. Özgen et al. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. European addiction research. 2020;26:223-232. PMID 32634814
  23. Özgen et al. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. 2021;50:54-67. PMID 34397296
  24. Price et al. Consensus Statement on Digital Health and Attention-Deficit/Hyperactivity Disorder by the European Network for ADHD (EUNETHYDIS): Modified Delphi Study. Journal of medical Internet research. 2026;28:e85638. PMID 42462051
  25. Kieling et al. ADHD in children and adults: diagnosis and prognosis. Current topics in behavioral neurosciences. 2012;9:1-16. PMID 21499858
  26. Spencer et al. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. Journal of pediatric psychology. 2007;32:631-42. PMID 17556405
  27. Schmidt et al. Developmental psychopathology: Attention Deficit Hyperactivity Disorder (ADHD). BMC psychiatry. 2009;9:58. PMID 19761584
  28. Salari et al. The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis. Italian journal of pediatrics. 2023;49:48. PMID 37081447
  29. Polanczyk et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International journal of epidemiology. 2014;43:434-42. PMID 24464188
  30. Polanczyk et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. The American journal of psychiatry. 2007;164:942-8. PMID 17541055
  31. Njardvik et al. Psychiatric comorbidity in children and adolescents with ADHD: A systematic review and meta-analysis. Clinical psychology review. 2025;118:102571. PMID 40245462
  32. Ayano et al. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. Journal of affective disorders. 2023;339:860-866. PMID 37495084